Physician

Abdul Mateen Nagaria, M.D.

According to 2025 Medicare claims, Abdul Nagaria, M.D. (NPI: 1023025707) practices nephrology in the Joplin, MO-KS market, with the plurality of this provider's patient population coming from Jasper, MO. This provider's primary affiliated billing organization is FREEMAN-OAK HILL HEALTH SYSTEM (NPI: 1679517023; TIN: 431704371) and primary practice location at 64804-3503. Nagaria is affiliated with the Mercy Health ACO, LLC (ACO ID: A2616) and Vytalize Health KS 25 LLC (ACO ID: A5671), participating under the MSSP model.

Nagaria's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 280 traditional Medicare patients, billed 1,439 HCPCS/CPT codes, and received $187,436 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 2,320 prescription claims across 260 beneficiaries totaling $216,051 in drug costs, led by Auryxia (Ferric Citrate). DME data shows 131 claims. Open Payments data shows 6 records totaling $181. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a higher plateau to a lower plateau, from $446,936 to $216,051. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	614	2,697	$245,034
2016	600	2,822	$249,097
2017	522	2,541	$234,825
2018	473	2,414	$229,469
2019	412	1,974	$212,287
2020	343	1,811	$209,949
2021	265	1,451	$223,489
2022	280	1,583	$212,335
2023	217	1,003	$153,730
2024	280	1,439	$187,436

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	299	3,549	$446,936
2016	294	3,290	$522,754
2017	279	2,925	$552,191
2018	243	2,369	$208,604
2019	245	2,497	$265,157
2020	252	2,440	$168,814
2021	214	2,047	$176,728
2022	206	2,069	$205,561
2023	203	2,082	$236,072
2024	260	2,320	$216,051

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	23	$1,118
2016	N/R	12	$226
2017	N/R	N/R	N/R
2018	N/R	27	$1,825
2019	N/R	29	$1,172
2020	N/R	29	$725
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	61	$974
2024	N/R	131	$2,337

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	52	382	$261
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	60	63	$127
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	77	268	$88
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	108	132	$64
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	57	145	$59

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Auryxia	Ferric Citrate	27	1,218	$98,989
Prosol	Parenteral Amino Acid 20% No.1	110	758	$22,705
Sevelamer Carbonate	Sevelamer Carbonate	48	2,212	$11,313
Eliquis	Apixaban	12	408	$7,882
Calcium Acetate	Calcium Acetate	80	3,149	$7,240

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	35	$621
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	27	$602
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	41	$577
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	12	$511
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	N	N/R	16	$25

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	6	$181	Otsuka America Pharmaceutical, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Abdul Mateen Nagaria, M.D.?

Tedicare shows public-source Medicare data for Abdul Mateen Nagaria, M.D. (NPI 1023025707), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Abdul Mateen Nagaria, M.D. have ACO affiliation data?

Abdul Mateen Nagaria, M.D. is shown with ACO affiliation data for Mercy Health ACO, LLC (MSSP, ACO ID A2616) and Vytalize Health KS 25 LLC (MSSP, ACO ID A5671).

What billing organization is linked to Abdul Mateen Nagaria, M.D.?

Abdul Mateen Nagaria, M.D. is linked to FREEMAN-OAK HILL HEALTH SYSTEM (billing NPI 1679517023) in the available physician profile data.

Does Abdul Mateen Nagaria, M.D. have Open Payments data?

Abdul Mateen Nagaria, M.D. has 6 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.